Home Tags Conjugates

Tag: Conjugates

Engineering Bispecific Antibodies to Cross the Blood-brain Barrier

Over the past decades, the development and regulatory approval of antibody-based therapeutics has progressed rapidly. But poor blood-brain barrier permeability has hampered the progress...

Danish Researchers Develop New Method for Efficient Tagging of Proteins

Researchers at the Aarhus University, Denmark's second oldest university, have developed an easier method to create DNA–protein conjugates. The method can potentially strengthen the work involved in diagnosing diseases. Their findings are published in the July online edition of Nature Chemistry [1]

Study Confirms DMOT4039A Shows Anticancer Activity in Patients with Pancreatic or...

A study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) being held May 30 - June 3, 2014 in Chicago, Ill, describes the results of a phase I clinical trial of the investigational agent DMOT4039A against pancreatic and ovarian cancers. In this early clinical trial with the goal of identifying possible risks and defining likely dosages, the drug was well tolerated and in some patients showed initial evidence of anti-cancer activity.
EORTC/GIMEA

EORTC/GIMEA Trial Does Not Show Benefits for Older AML Patients

Results of a randomized phase III trial evaluating the efficacy and toxicity of sequential gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit in...

Dual-Warhead Takes Antibody Drug Conjugates a Step Further

Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing a cell-free protein synthesis technology, presented the first scientific data involving...

New Linker Technology May Improve Antibody-guided Therapies

Chemists at The Scripps Research Institute (TSRI) have devised a new technique for connecting drug molecules to antibodies to make advanced therapies.

ADC Therapeutics and Genmab Agree to Develop Antibody-drug Conjugate

Earlier this week Swiss-based oncology drug development company ADC Therapeutics Sarl and Danish Genmab A/S agreed to develop a new antibody-drug conjugate (ADC) combining HuMax®-TAC antibody...

New CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Anti-tumor Activity in...

Preclinical data from SGN-CD33A (Seattle Genetics, Inc), a novel CD33-directed antibody-drug conjugate (ADC) in development for the treatment of acute myeloid leukemia (AML) presented at...

The Next Advancements in Cancer Drug Development: Antibody-Drug Conjugates

The annual meeting of the American Society of Clinical Oncology (ASCO) conference held June 1-5, 2012 in Chicago, IL offered a wealth of new...